Gunnar Kaufmann
Principal investigator, leads ONCTERNAL THERAPEUTICS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$2.2MFederal grants as PI2 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
2 awards · $2.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 1, 2021 | NIH | SBIR Phase II First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development | $1.9M | ONCTERNAL THERAPEUTICS, INC. |
| Sep 1, 2021 | NIH | STTR Phase I Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA) | $298K | ONCTERNAL THERAPEUTICS, INC. with UNIVERSITY OF TENNESSEE HEALTH SCI CTR |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#885
Awards as PI#1,252
Patents#273
Companies
- ONCTERNAL THERAPEUTICS, INC.Leads (SEC Form D) · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.